Blair William & Co. IL Sells 40,880 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Blair William & Co. IL trimmed its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 1.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,360,904 shares of the biopharmaceutical company’s stock after selling 40,880 shares during the period. Blair William & Co. IL owned about 1.80% of Dynavax Technologies worth $26,513,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the business. Renaissance Technologies LLC grew its position in shares of Dynavax Technologies by 2.2% in the 2nd quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock valued at $27,830,000 after purchasing an additional 53,600 shares during the period. WINTON GROUP Ltd lifted its stake in Dynavax Technologies by 9.3% in the second quarter. WINTON GROUP Ltd now owns 82,403 shares of the biopharmaceutical company’s stock valued at $925,000 after buying an additional 7,025 shares in the last quarter. State of New Jersey Common Pension Fund D acquired a new position in shares of Dynavax Technologies in the second quarter valued at approximately $1,811,000. Choreo LLC bought a new stake in shares of Dynavax Technologies during the second quarter worth $363,000. Finally, Rhumbline Advisers raised its holdings in shares of Dynavax Technologies by 1.8% during the second quarter. Rhumbline Advisers now owns 310,805 shares of the biopharmaceutical company’s stock worth $3,490,000 after acquiring an additional 5,379 shares during the period. 96.96% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on DVAX shares. The Goldman Sachs Group reduced their target price on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $29.00 price objective on shares of Dynavax Technologies in a research report on Wednesday, August 7th. Finally, StockNews.com lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, May 28th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Dynavax Technologies currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.67.

Dynavax Technologies Stock Down 0.4 %

Dynavax Technologies stock opened at $11.21 on Thursday. The company has a current ratio of 14.18, a quick ratio of 13.18 and a debt-to-equity ratio of 0.35. Dynavax Technologies Co. has a 1-year low of $9.74 and a 1-year high of $15.15. The company has a fifty day simple moving average of $11.02 and a 200 day simple moving average of $11.49. The company has a market cap of $1.47 billion, a P/E ratio of 186.83 and a beta of 1.37.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.02. Dynavax Technologies had a return on equity of 2.76% and a net margin of 6.88%. The company had revenue of $73.80 million during the quarter, compared to analysts’ expectations of $76.92 million. During the same quarter last year, the company earned $0.03 EPS. Research analysts anticipate that Dynavax Technologies Co. will post 0.16 earnings per share for the current fiscal year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.